Longitude Capital leads $68 mln funding in Kala Pharmaceuticals

Longitude Capital led a $68 million Series C preferred stock financing in Kala Pharmaceuticals, Inc., which develops ophthalmic products. New investors in the funding included OrbiMed, Vivo Capital and CAM Capital. Existing investors in the funding included RA Capital Management, Wellington Management Company LLP, Polaris Partners, Lux Capital, CVF, LLC and others. Gregory Grunberg, managing director at Longitude Capital, and Chen Yu, managing partner at Vivo Capital, are joining Kala's board as new board members.

North AmericaUSBriefs